Clinical Trial Update: Exercise for Patients With Renal Cell Cancer Receiving Sunitinib [Phase 3]

View source ↗

Summary

This entry reports a Phase 3 clinical trial investigating exercise as an adjunctive approach for patients with renal cell carcinoma treated with sunitinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Renal Cell Carcinoma | Phase 3 | Status: UNKNOWN